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Nephrotoxicity is one of the most important side effects and
therapeutical limitations of aminoglycoside antibiotics,
especially gentamicin. Despite rigorous patient monitoring,
nephrotoxicity appears in 10–25% of therapeutic courses.
Traditionally, aminoglycoside nephrotoxicity has been
considered to result mainly from tubular damage. Both lethal
and sub-lethal alterations in tubular cells handicap
reabsorption and, in severe cases, may lead to a significant
tubular obstruction. However, a reduced glomerular filtration
is necessary to explain the symptoms of the disease. Reduced
filtration is not solely the result of tubular obstruction and
tubular malfunction, resulting in tubuloglomerular feedback
activation; renal vasoconstriction and mesangial contraction
are also crucial to fully explain aminoglycoside
nephrotoxicity. This review critically presents an integrative
view on the interactions of tubular, glomerular, and vascular
effects of gentamicin, in the context of the most recent
information available. Moreover, it discusses therapeutic
perspectives for prevention of aminoglycoside
nephrotoxicity derived from the pathophysiological
knowledge.
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INTRODUCTION: AMINOGLYCOSIDE ANTIBIOTICS
AND NEPHROTOXICITY
Aminoglycoside antibiotics (AG) are widely used in the
treatment of a variety of infections (for example, ocular,
pulmonary, and intestinal infections) produced by Gram-
negative bacteria and bacterial endocarditis.1 Their cationic
structure, which depends on the number of amino groups
and on their distribution within the molecule, seems to have
an important role in their toxicity, mostly affecting renal
(nephrotoxicity2) and hearing (ototoxicity) tissues in which
they accumulate. In spite of their undesirable toxic effects,
AGs still constitute the only effective therapeutic alternative
against germs insensitive to other antibiotics. This is
primarily because of their chemical stability, fast bactericidal
effect, synergy with betalactamic antibiotics, little resistance,
and low cost.3 In spite of being one of the most nephrotoxic
AG, gentamicin is still frequently used as a first- and second-
choice drug in a vast variety of clinical situations. Moreover,
this aminoglycoside has been widely used as a model to study
the nephrotoxicity of this family of drugs, both in experi-
mental animals and human beings.4–6 Most of the available
data on the mechanisms responsible for AG nephrotoxicity
has been obtained from gentamicin, especially at the
preclinical level, in animal models or cell culture studies.
Although there are some reviews about the mechanisms
explaining the toxic effects of gentamicin in the tubular
epithelium, renal vasculature, and glomeruli, they lack an
integrative view that brings together glomerular and tubular
effects and their possible interplays. Thus, the purpose of this
article is to review the effects of gentamicin in several kidney
compartments with an integrative approach in order to
further explain its nephrotoxicity.
NEPHROTOXICITY OF GENTAMICIN
Incidence and risk factors
The incidence of aminoglycoside nephrotoxicity has progres-
sively increased since its introduction, until reaching 10–25%
of the treatments, despite the accurate control and follow-up
exercised on patients.5–9 Clinical studies lead to the conclu-
sion that the incidence of renal damage varies depending
on the target population,10–13 which indicates that some
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individuals seem to be more sensitive than others. Table 1
shows the most important risk factors for the nephrotoxicity
of gentamicin and, in general, of AGs.14–17
Clinical manifestations
The typical clinical manifestation of aminoglycoside toxicity
is nonoliguric or even polyuric renal excretion dysfunc-
tion,10,18–20 accompanied by an increase in plasma creatinine,
urea and other metabolic products of the organism,
proteinuria, enzymuria, aminoaciduria, glycosuria, and
electrolyte alterations (hypercalciuria, hypermagnesuria,
hypocalcemia, and hypomagnesemia).21,22
TUBULAR EFFECTS
The tubular toxicity of gentamicin presents two aspects:
(i) the death of tubular epithelial cells, mainly within the
proximal segment, with a very important inflammatory
component associated and (ii) the nonlethal, functional
alteration of key cellular components involved in water and
solute transport.
Mechanisms of tubular cell death
A central aspect of aminoglycoside nephrotoxicity is their
tubular cytotoxicity. Treatment of experimental animals with
gentamicin results in apoptosis23–25 as well as necrosis26 of
tubular epithelial cells. In culture, gentamicin also causes
both apoptosis27 and necrosis of these cells.28 The phenotype
of death might depend on the concentration of the drug, as
with other cytotoxic compounds such as cisplatin and
H2O2.
29,30 It might also depend on the concurrence of other
triggering or predisposing factors, such as the degree of
ischemia, on specific points of the renal parenchyma.
Apoptosis is an ATP-requiring process. When the cell’s ATP
reserve drops, the death mode loses the typical characteristics
of apoptosis and acquires those of necrosis.31 Hypoxia
inhibits respiration, ATP production, and sensitizes cells to
Fas ligand32 and induces cell death.33,34 However, the most
commonly observed phenotype in vitro is apoptosis, probably
because it is necessary to expose cultured cells to high
concentrations of the drug (41 to 2mg/ml) to observe a
modest cytotoxic effect.28,35,36 Figure 1 graphically depicts the
Table 1 | Risk factors of aminoglycoside antibiotics related to
patient and treatment characteristics, and to the
concomitant administration of other drugs
Patient Treatment Other drugs
Older age Longer treatment NSAIDs
Reduced renal function Higher dosage Diuretics
Pregnancy Split dosage Amphotericin
Dehydration — Cisplatin
Renal mass reduction — Cyclosporin
Hypothyroidism — Iodide contrast media
Hepatic dysfunction — Vancomycin
Metabolic acidosis — Cephalosporin
Sodium depletion — —
Abbreviation: NSAIDs, nonsteroidal anti-inflammatory drugs.
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mechanisms of cytotoxicity detailed in the following
paragraphs.
Gentamicin cytotoxicity occurs in those cell types in which
the drug accumulates. In the kidneys, these cells constitute
the epithelial cells in the cortex, mainly in the proximal
tubule of experimental animals37 and humans,16 and also in
the distal and collecting ducts.38 A higher accumulation of
gentamicin in these cells is consistent with the expression of
a transporter of proteins and cations, namely, the giant
endocytic complex formed by megalin and cubilin, which is
restricted to the proximal tubule. This complex is known to
transport gentamicin and, in general, AGs, by endocytosis.39
These drugs then traffic through the endosomal compart-
ment and accumulate mostly in lysosomes, the Golgi, and
endoplasmic reticulum.40–41 Gentamicin binds to membrane
phospholipids, alters their turnover and metabolism, and, as
a consequence, causes a condition known as phospholipi-
dosis that has been observed in humans7 and experimental
animals treated with the drug.42,43 Lysosomal phospholipi-
dosis results from (i) the reduction in the available negative
charge necessary for the correct function of phospholipases44
and (ii) inhibition of A1, A2, and C1 phospholipases.4,45,46
Phospholipidosis correlates tightly with the level of toxicity
of aminoglycosides.43,47,48 Moreover, agents protecting from
phospholipidosis, such as polyaspartic acid, also prevent
aminoglycoside nephrotoxicity.49–51 However, the effect of
polyaspartic acid has been ascribed to its capacity to bind
gentamicin and thus to prevent its union to phospholipids.52
Binding to phospholipids is also a requirement for gentami-
cin endocytosis,53,54 indicating that further investigation is
necessary to ascertain the exact role of phospholipidosis in
tubular cell death.
When the concentration of aminoglycoside in endosomal
structures exceeds an undetermined threshold, their mem-
brane is disrupted and their content, along with the drug,
is poured into the cytosol.55,56 Cytosolic gentamicin then
acts on mitochondria directly and indirectly,57,58 and thus
activates the intrinsic pathway of apoptosis, interrupts the
respiratory chain, impairs ATP production,58,59 and produces
oxidative stress by increasing superoxide anions and hydroxyl
radicals,60,61 which further contributes to cell death. The
indirect mitochondrial effect is mediated by increasing Bax
levels62 through the inhibition of its proteosomal degrada-
tion.35 In addition, the lysosomal content bears highly active
proteases named cathepsins, which are capable of producing
cell death.63 Cathepsin-mediated cell death occurs through
apoptosis by directly cleaving active executioner caspases and
indirectly unleashing the intrinsic pathway through the
proteolytic activation of Bid.64,65 In high amounts, cathepsins
also cause a massive proteolysis that, especially under low
ATP conditions, leads to a rapid, necrotic-like mode of cell
death.66
In the endoplasmic reticulum, gentamicin inhibits protein
synthesis,67,68 impairs translational accuracy,69 and might
interfere with the correct posttranslational protein folding.62
This generates endoplasmic reticulum stress and activates the
unfolded protein response that, on continuous stimulation,
activates apoptosis through calpains and caspase 12.70–72
Finally, activation of the extracellular calcium-sensing
receptor (CaSR) with gentamicin and other aminoglycosides
has also been shown to induce a mild degree of apoptosis in
CaSR-expressing tubule cells and not in those lacking it.
However, CaSR is also expressed in gentamicin-resistant cells
including bone, brain, colon, parathyroid gland, smooth
muscle, endothelial cells, and so on. Clearly, more informa-
tion is necessary to clarify the exact role and the relative
weight of CaSR stimulation in tubule cell death induced by
aminoglycosides.
Sub-lethal alterations in tubular reabsorption
In experiments carried out with cultured cells or membrane
vesicles from tubular cells, it has been shown that gentamicin,
independently of cell injury, inhibits a variety of cell
membrane transporters of both the brush-border and the
basolateral membrane (reviewed in Mingeot-Leclercq and
Tulkens20) including (i) Na-Pi cotransporter73 and Na-H
exchange;74 (ii) carrier-mediated dipeptide transport;75 (iii)
electrogenic Na transport;76 and (iv) Na-K adenosine
triphosphatase.77,78 Transport inhibition affects tubular
reabsorption, but it may also compromise cell viability
(Figure 1). For example, Na-K adenosine triphosphatase is a
key component of cell volume homeostasis, and deregulated
swelling may lead to necrosis or apoptosis.79,80 As early as
30min after gentamicin renal perfusion21 or 3 h after
gentamicin administration to rats,81 deficient reuptake of
calcium and magnesium is observed, leading to hypercalciur-
ia, hypermagnesiuresis, and hypomagnesemia, before altera-
tions in renal handling of Naþ and Kþ , and before
detectable signs of renal damage and toxicity are evident.
Gentamicin is transported by and also competes with
proteins, organic cations, and other molecules for the
megalin–cubilin endocytic complex in the proximal tubule,
and thus impairs their reabsorption.82–85
Tubular effects cannot solely explain the reduced
glomerular filtration rate
The spilling of tissue and cellular residues to the tubular
lumen partially or totally obstructs the tubules.86,87 Tubular
obstruction reduces, or even voids, the excretory function of
the affected nephrons. In addition, it increases the hydrostatic
pressure inside the tubule and in the Bowmans’ capsule,
which reduces filtration pressure gradient and, therefore, the
glomerular filtration rate (GFR). Moreover, the increase of
intratubular pressure increases the leak of the ultrafiltrate
toward the interstitial space (backleak) and peritubular
capillaries, and, thus, decreases excretion of the filtrate
products.86 Accordingly, tubular obstruction may account for
a part of the reduced filtration caused by gentamicin.
However, in mild cases and early stages of severe cases, that
is, in the absence of significant tubular obstruction, a relevant
accumulation of creatinine and uremic products can be
detected in the blood, which is usually the evidence that alerts
Kidney International (2011) 79, 33–45 35
JM Lopez-Novoa et al.: Nephrotoxicity of gentamicin rev iew
on the underlying renal damage, and indicates that, by
that time, GFR is already reduced. In the absence of
significant nephron obstruction, an increase in plasma
creatinine (and other products) can only be explained by a
reduced GFR.
Tubular damage leads to a dysfunctional reabsorption
process that produces an excessive delivery of water and
electrolytes to the distal part of the nephron, which in turn
triggers the tubuloglomerular feedback (TGF) mechanism.
TGF is brought about by an angiotensin-II and adenosine-
mediated afferent and efferent arteriole effects, and the
subsequent decrease in GFR.88,89 TGF is activated as a
protective mechanism to avoid massive loss of water and
electrolytes.90 The TGF mechanism is known to adapt in a
period of time ranging from 1 to 24 h.91,92 Therefore, its role
in the reduction of glomerular filtration should, theoretically,
disappear after this interval. However, GFR continues to
decrease as long as gentamicin treatment is maintained. As
described in the following sections, oxidative stress, inflam-
mation, and the release of vasoconstrictors induce mesangial
and vascular contraction (see below). These may explain why
GFR remains low even in the absence of an active TGF and of
significant tubular obstruction. In addition, it can also be
hypothesized that gentamicin might inhibit or modulate
TGF-adaptive mechanisms.
GLOMERULAR EFFECTS
The glomerulus is the first part of the nephron to come
into contact with chemical agents. Gentamicin has glomer-
ular effects that alter filtration (Figure 2). (i) Gentamicin
produces mesangial contraction (reviewed in Martı´nez-
Salgado et al.93) and results in Kf (ultrafiltration coefficient)
and GFR reduction;94,95 (ii) gentamicin also stimulates
mesangial proliferation paralleled by an increase in apoptosis
of these cells, which basically compensate each other;93,96 (iii)
despite the fact that gentamicin does not generate significant
morphological changes in the glomerulus, in high-dose
treatments, a slight increase in size, alteration of their round
shape and density, and a diffuse swelling of the filtration
barrier associated with neutrophil infiltration have been
detected,97 although their pathophysiological significance is
uncertain; and (iv) loss of glomerular filtration barrier
selectivity, due to the neutralization of its negative charges,98
contributes to proteinuria, especially under circumstances in
which tubular reabsorption is impaired such as in tubular
necrosis.
Early studies demonstrated that gentamicin reduces the
number and pore size of glomerular endothelial fenes-
trae,99–101 correlating with a decrease in the sieving coefficient
of low-molecular-weight proteins such as lysozyme,100 and
supporting a reduction in GFR. These effects seem to be the
consequence of mesangial contraction. Gentamicin activates
contraction of cultured mesangial cells and isolated glomer-
uli,102,103 and thus reduces Kf. Several factors induced by
gentamicin increase intracellular calcium concentration and
cause mesangial cell contraction (reviewed in Martı´nez-
Salgado et al.93; Figure 2). They include (i) platelet-activating
factor (PAF) secretion and autocrine action;102 (ii) activation
of the renal renin–angiotensin system; (iii) production
and action of vasoconstrictors such as endothelin-1 and
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thromboxane A2 arising from endothelial dysfunction or
imbalance;104 (iv) CaSR stimulation; and (v) increase in reactive
oxygen species (ROS) production and oxidative stress.105
Activation of phospholipase A2 has also been associated
with the synthesis of some of the above mediators and with
the effect of gentamicin on mesangial cells.103 Phospholipase
A2 catalyzes the formation of arachidonic acid, a soluble
phospholipid. Arachidonic acid generates, through cycloox-
ygenase, the synthesis of thromboxane A2 which leads to
mesangial contraction. PAF is also synthesized from
the soluble phospholipids that result from phospholipase
A2 activity. PAF is recognized as an important mediator of
mesangial contraction, which decreases Kf and GFR.
106–108 In
fact, PAF antagonists partially inhibit gentamicin-induced
reduction in GFR,95,109,110 and mesangial contraction in
isolated glomeruli and cultured mesangial cells.92,102,110
In rats treated with gentamicin, both proliferation and
apoptosis take place at the same time in the mesangial
compartment. Both effects apparently compensate one
another, because no net variation in the number of mesangial
cells has been reported.93,111 Mesangial proliferation is
mediated by calcium-dependent AP-1 activation.96 Mesangial
cell apoptosis is mediated by increased ROS96,111 and
probably by nitric oxide (NO) overproduction.93 Gentamicin
stimulates inducible nitric oxide synthase (iNOS) expression
and NO production in isolated glomeruli and mesangial
cells.112–114 Excessive NO production due to expression of
iNOS, especially under oxidative stress circumstances, inter-
acts with superoxide anion to forms peroxynitrite, which
causes nitrosative stress and cytotoxic effects.115 The role of
mutually counterbalancing mesangial apoptosis and prolif-
eration is not clear. Probably, one is the homeostatic
consequence of the other, in order to maintain tissue
integrity. Gentamicin might cause a mild degree of apoptosis
in mesangial cells followed by a repairing proliferation.
Alternatively, gentamicin might promote the proliferation of
mesangial cells (through the increment in Ca2þi ) that, in
the absence of tissue damage, would lead to apoptosis.93
However, both increased proliferation and apoptosis have
been detected in cultured mesangial cells treated with
gentamicin,111 which obscures both of these interpretations.
As argued in Martı´nez-Salgado et al.,93 in vivo the primary
effect would be apoptosis, with subsequent homeostatic
proliferation.
VASCULAR EFFECTS
Gentamicin induces a reduction in renal blood flow
(RBF),116,117 which is the consequence of an increased
resistance of the renal vascular bed rather than that of a
lower perfusion pressure.118 A lower RBF causes GFR to
fall119 (see Figure 3), and sensitizes tubule cells to cell death
by reduction of oxygen and ATP availability (as explained
above). RBF reduction arises initially (i) from the activation
of TGF by the handicapped tubular reabsorption, in order to
prevent massive fluid and electrolyte loss and (ii) progres-
sively, superseding TGF adaptation, by production of
vasoconstrictors within the renal vascular tree and mesangial
compartment; and by direct effects of gentamicin on vascular
cells (Figure 3).
The production of several vasocontrictors is increased
on gentamicin treatment, including endothelin-1,104 PAF,
and arachidonic acid metabolites, mainly prostaglandins and
thromboxane A2,103,120,121 arising from endothelial and
mesangial cells,93 as explained in the previous section. They
act in a paracrine manner on vascular myocytes and cause
vasoconstriction. In addition to stimulating the production
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of vasoconstrictors, gentamicin also blocks the synthesis of
vasodilator prostaglandins.120 Endothelial NO synthase-
derived NO, at low levels, mediates physiological vasodilata-
tion, whereas excessive NO production due to the over-
expression of iNOS (see above, section ‘Vascular effects’) can
cause cytotoxic effects in surrounding cells. NO interacts with
superoxide anion to form peroxynitrite, which induces
protein and cell damage and uncouples endothelial NO
synthase to become a dysfunctional superoxide-generating
enzyme that contributes to vascular oxidative stress.122
Gentamicin also impairs vascular smooth muscle-relaxing
capacity through an unraveled mechanism, theoretically
contributing to vasoconstriction and RBF reduction, to an
undetermined extent.123 However, gentamicin has also been
shown to relax isolated, precontracted arteries,124,125 through
the inhibition of phospholipase C, protein kinase C, and
calcium movements.124,125 This relaxing effect is exerted
directly on smooth muscle cells and occurs despite
gentamicin inhibiting the release of endothelium-derived
relaxing factor, secondary to inhibition of PLC.126
Finally, leukocyte margination, leading to vascular plug-
ging, congestion, and infarction, is induced by gentamicin in
retinal vessels after 48–72 h of treatment.127 It can be
speculated that vascular plugging contributing to ischemia
might also occur in the kidneys, especially under a strong
proinflammatory environment, although this has to be
specifically corroborated.
INTEGRATIVE PATHOPHYSIOLOGY OF GENTAMICIN
NEPHROTOXICITY
Classically, the nephrotoxicity of gentamicin has been
considered as a tubulopathy in which tubular damage and
tubular dysfunction are the main cause of renal insufficiency.
This may explain some clinical observations, such as
proteinuria, enzymuria, and electrolytic alterations. However,
as explained in the section ‘Tubular effects cannot solely
explain the reduced glomerular filtration rate’, in the absence
of tubular obstruction, tubular damage itself cannot account
for a reduced GFR without the concourse of extratubular
determinants. GFR reduction needs to be justified in order to
fully explain the alterations in renal excretory function,
leading to the accumulation of metabolic products in the
blood, azotemia, uremia, and the whole renal syndrome
produced by gentamicin.
Tubular and glomerular mechanisms differentially
contribute to the reduced GFR
Tubular dysfunction leads to the loss of fluid and electrolytes
that swiftly fire the TGF response, which reduces RBF and
GFR to the appropriate level. Because, under physiological
circumstances B99% of water and electrolytes in the
ultrafiltrate are reabsorbed along the tubule, a drastic
reduction in GFR must be accomplished to compensate for
a small reduction in tubular reabsorption, thus preventing
the life-threatening loss of water and electrolytes. That is why
even a mild injury to the tubular epithelium may bring about
a pathological reduction in GFR and renal failure. However,
TGF adapts within hours and its control over GFR is lost
even in the presence of an increasing tubular incompetence.
Yet, clinical and experimental observations demonstrate that,
despite TGF adaptation, GFR grows lower as gentamicin-
induced damage progresses, as described in previous sections.
Figure 4 shows the mechanisms leading to a reduced GFR.
It can be observed that tubular malfunction leading to a
defective reabsorption is the only mechanism that causes no
GFR reduction directly, although it decreases GFR indirectly
by activating the TGF mechanism, at least transitorily.
Tubular obstruction increases progressively with tubular
damage, as does its contribution to the reduced GFR. As
such, it only partially explains the whole reduction in GFR,
especially in the initial phase of acute kidney injury, which is
the most relevant clinical situation. In these circumstances
(Figure 5), a number of factors may hold GFR low in the
absence of TGF-mediated control. Contracting factors
produced by mesangial, vascular, and tubular cells, including
ROS, PAF, angiotensin-II, and endothelin-1 act in an
autocrine and paracrine manner to induce contraction of
glomerular vessels and mesangial cells, which reduce RBF and
Kf, respectively, and lower GFR. A question for the future is if
a part of the reduction in GFR caused by gentamicin would
still occur, should tubular alterations be completely and
specifically prevented, or, whether most glomerular and
vascular effects are, at least partially, independent of tubular
damage. As explained above, gentamicin-induced mesangial
activation and contraction have been documented
in cultured, isolated mesangial cells,93 indicating that no
tubular-derived stimulation is necessary for these effects.
In addition, reduced GFR and RBF may contribute to
aggravating gentamicin-induced tubular damage,128 probably
because they limit oxygen and nutrient availability to tubular
cells and facilitate oxidative stress, as it has been demon-
strated in the ischemic renal failure.
Central role of oxidative stress and inflammation: a loop of
damage amplification and a connection between tubular
and glomerular mechanisms
Oxidative stress has been suggested to have a key role in
gentamicin nephrotoxicity.129–131 This is mainly based on a
myriad of studies conducted in experimental models demon-
strating that cotreatment with a variety of antioxidants protects
from gentamicin-induced renal damage,61,117,132,133 although
clinical data is not so conclusive.134 Gentamicin directly
increases the production of mitochondrial ROS,58 which
(i) are able of damaging many cellular molecules including
proteins, lipids, and nucleic acids, thus impairing cell function
and leading to cell death; (ii) contribute to mesangial and
vascular contraction (as described in sections ‘Glomerular
effects’ and ‘Vascular effects’); and (iii) participate in
inflammation.
The nephrotoxicity of gentamicin has been shown
to involve an inflammatory response in experimental
animals135,136 and humans,137 with cell infiltration, activation
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of resident cells, increased cytokine production,138,139 and
capillary hyperpermeability.140 The inflammatory response,
initially unleashed as a defense and repair mechanism, when
globally considered seems to contribute to renal damage
progression. In fact, strategies that protect from gentamicin-
induced renal damage usually inhibit the inflammatory
response.135,141 In this sense, ROS are known to participate
in the inception and signaling of inflammation,142 which
might explain why antioxidants are very effective at softening
the renal damage inflicted by gentamicin117,143,144 (Figure 6)
and, in general, by other tubular necrosis-inducing nephro-
toxins.134,145 ROS such as superoxide anion146 and hydrogen
peroxide147 activate nuclear factor kB, which has a key role
in the inception of the inflammatory process. Indeed,
nuclear factor kB inhibitors protect the kidney against
gentamicin-induced damage.148 Nuclear factor kB induces
the expression of proinflammatory cytokines149 and iNOS.150
As described above, iNOS-derived NO can react with
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superoxide anion and produce peroxinitrite, a highly reactive
radical that contributes to cell damage and reduced vascular
relaxation.
It can be speculated that the effect of antioxidants might
be related to a combined action at different levels, including
the following: (i) softening of gentamicin’s direct cytotoxicity
(as explained above); (ii) inhibiting vasoconstriction and
mesangial contraction; and (iii) an antiinflammatory action.
However, there is little information on the ability
of antioxidants to modulate the direct cytotoxic effect of
gentamicin on cultured tubule cells. To our knowledge, only
Juan et al.151 have reported a protective effect in this sense. In
their article, tetramethylpyrazine reduces ROS accumulation
and apoptotic events in rat renal NRK-52E cells. However,
the effect of tetramethylpyrazine on cell viability is not
reported. Because there are many apoptotic and necrotic
pathways leading to cell death as a consequence of gentamicin
action, and because their redundancy and hierarchical
organization are not well understood, the magnitude
of the direct cytoprotection afforded by ROS inhibition is
unknown.
In any case, it is reasonable to think that the inflammatory
response acts as an amplifying mechanism of damage
(Figure 6). Initially, cell destruction through necrosis would
lead to the onset of an inflammatory response. Tissue debris
and cell content shed into the extracellular space trigger
inflammation,152 whereas an exaggerated inflammation
would contribute to further damage that, in turn, would
exacerbate the inflammatory response.153 Inflammation also
activates glomerular cells, such as mesangial cells, podocytes
and epithelial cells, endothelial cells, and resident and
infiltrated leukocytes. These, in turn, produce cytokines
and growth factors that contribute to the pathophysiological
process with different effects (Figure 6), including amplifica-
tion of tubular damage.154 As such, inflammation and
Tubular necrosis
Glomerular filtration
TGF TO VC and MC
AKI evolution
Figure 5 |Comparative temporal evolution of the acute kidney
injury (AKI), tubular necrosis, glomerular filtration,
tubuloglomerular feedback, and vascular and mesangial
contraction on treatment with gentamicin. Initially,
tubuloglomerular feedback (TGF) controls glomerular filtration
rate. As TGF adapts, increasing tubular obstruction (TO), and
vascular and mesangial contraction (VC and MC) take over and
make GFR progressively lower.
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Figure 6 |Role of inflammation in the amplification of tubular, glomerular, and vascular effects of gentamicin. PAF, platelet-
activating factor; RBF, renal blood flow; ROS, reactive oxygen species; TLRs, toll-like receptors.
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oxidative stress provide a connection between tubular
necrosis and glomerular and vascular activation and
contraction, which ultimately further contribute to tubular
damage, mainly through a reduction in RBF.
CLINICAL IMPLICATIONS FOR THE PREVENTION OF
NEPHROTOXICITY
Prevention of nephrotoxicity is an unmet therapeutic
objective that will improve the pharmacotoxicological profile
and the clinical utility of many drugs significantly, including
AGs. In many cases, nephrotoxicity is the most important
limitation to the dosage or intensity of the therapeutic
regimen, and may lead to serious health complications and
even death in determined cases. Nephrotoxicity is a concern
in all clinical settings, but takes special relevance among
critically ill patients. Indeed, it is estimated thatB25% of the
100 most used drugs in intensive care units are potentially
nephrotoxic,155 and that nephrotoxicity is responsible for
10–20% of acute renal failure cases.156 Besides a correct
monitoring, maintenance of patient’s hydration, and applica-
tion of dialysis when necessary, there are no therapeutic tools
available to prevent or palliate drug nephrotoxicity. There are
no or very few tailored preventive strategies for individual
nephrotoxic drugs, based on specific mechanisms of action.
Nonetheless, this is another challenge for the future.
In addition to the identification of less toxic compounds,
several new strategies for the prevention of aminoglycoside
nephrotoxicity are currently under different degrees of
development, mostly at the preclinical level.
Inhibition of tubular accumulation
A proposed strategy focuses on finding drugs that prevent the
accumulation of aminoglycosides by interfering with trans-
port mechanisms. An obvious target is the megalin-related
endocytic machinery responsible for AG transport and
accumulation in tubular and auditory cells. Inhibition of
aminoglycoside transport can be approached by administer-
ing (i) competitors for the receptor that displace aminoglyco-
sides from binding to it or (ii) specific inhibitors of this
endocytic pathway. Certain protein, fragments thereof and
basic peptide ligands of megalin reduce the accumulation of
gentamicin in cultured tubular cells and renal tubuli in vivo
by inhibiting drug binding to the brush border.85,157,158
Statins have been shown to reduce gentamicin accumulation
in tubule cells and renal damage through a mechanism
involving geranyl isoprenoids.159 Megalin-mediated endocy-
tosis involves other proteins with binding, adaptor, and
unknown functions, such as cubilin, disabled-2, nonmuscle
myosin heavy chain IIA and b-actin, which seem to
participate in endocytic trafficking.160 These proteins, and
others resulting from a deeper knowledge of the endocytic
mechanisms, are potential targets for pharmacological
prevention of aminoglycoside accumulation. Indeed, genetic
disruption of myosin VI161 or treatment with the myosin
inhibitor blebbistatin160 reduces the uptake of proteins
transported by the megalin complex. Myosin VI knockout
mice show albuminuria with no alterations in urine output
or electrolyte excretion. These initial results show a potential
avenue for further exploration. Yet, the clinical consequences
(for example, proteinuria) of interfering with megalin-
mediated endocytosis as a mechanism of nephroprotection
need to be determined in the short- and long term. In this
line, myosin VI knockout mice show tubular dilation and
fibrosis, consistent with persistent proteinuria.161
Cotreatment with renoprotective drugs
Another strategy relies on nephroprotective drugs for
cotreatment along with aminoglycosides. At the preclinical
level, many molecules have been shown to exert protective
effects on drug nephrotoxicity and, specifically on aminogly-
coside nephrotoxicity. By far, most of the studies have tested
the ability of antioxidants to alleviate aminoglycoside
nephrotoxicity. With one exception studied in patients,162
all of them have been conducted in experimental animals.
Preclinical studies offer unambiguous information on the
beneficial effects of antioxidants. However, these results need
to be further explored in the clinical setting, as promising,
although inconsistent, results have been obtained on the
protection exerted by antioxidants on the nephrotoxicity of
other drugs.134 In most studies in which inflammation has
been evaluated, it is concluded that they might exert
their effects through a cytoprotective and antiinflammatory
action.
Improvement of RBF may also attenuate aminoglycoside
nephrotoxicity, even independently from tubular damage.162
An increased RBF by preglomerular or general vasodilatation
can enhance GFR and attenuate the tubular damage caused
or amplified by the reduced flow. In this sense, promising
results have been obtained in animals with PAF inhibitors,
although they have not progressed further into human
investigation. This could be an attractive strategy to pursue.
In general, vasodilators also relax mesangial cells and
augment Kf. As such, the increase in GFR is not only
the result of hemodynamic improvement but also of Kf
modulation. Thromboxane A2 inhibitors have been used in
one study with protective results.120 Calcium antagonists
have also been used with contradictory results at the
preclinical level. We have found only two studies conducted
in humans. They document protection afforded by calcium
channel blockers verapamil and nifedipine on gentamicin
nephrotoxicity.162,163 The effect of calcium antagonists may
depend on the relative level of contraction of preglomerular
and postglomerular vessels and mesangial cells, and on the
weight of vasoconstriction and mesangial contraction in the
overall effect of a determined experimental or clinical
therapeutic regimen with aminoglycosides. This, in turn,
may also depend on the dose and length of treatment, drug
accumulation, and so on. A note of caution should also
be introduced here, because the clinical consequences of
augmenting GFR without a parallel amelioration of tubular
damage may result in massive proteinuria, and water and
electrolytic loss, which need to be addressed.
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Other strategies
Another potentially nephroprotective effect that should be
pursued is the blockade of the immune response. In fact,
genetic knockdown of toll-like receptor-4 has been shown to
alleviate the renal lesion induced by cisplatin164 and ischemia
reperfusion165 in mice, in which inflammation has a central
pathological role. Indeed, ROS are involved in toll-like
receptor-mediated inflammation.166 Perhaps, cocktails con-
taining several drugs aimed at providing protection against
tubular damage and inflammation, and improvement of
renal hemodynamics should be evaluated at the preclinical
and clinical levels.
CONCLUSIONS AND PERSPECTIVES
An integration of tubular, glomerular, and vascular effects of
aminoglycosides based on the evidence discussed in this
paper is consistent with an important component of tubular
injury. In severe degrees of acute kidney injury induced by
gentamicin, tubular obstruction may account, at least partly,
for the reduced GFR. However, in mild cases and early stages
of severe cases, that is, in the absence of significant tubular
obstruction, GFR reduction can only be explained by
extratubular mechanisms, namely, mesangial and vascular
contraction. These later result from (i) the TGF mechanism,
with the temporal restriction explained in section ‘Tubular
effects cannot solely explain the reduced glomerular filtration
rate’; (ii) direct mesangial and vascular contraction; and
(iii) indirect mesangial and vascular contraction produced by
inflammation and paracrine mediators. Inflammation is
known to result from tissue damage, specially arising from
cell necrosis. Still, it remains to be elucidated (i) whether all
the inflammatory responses are the consequences of tubular
damage or whether they are also partly activated or amplified
by tubular necrosis-independent mechanisms; and (ii) what
is the contribution of direct extratubular effects of gentami-
cin to the overall syndrome, which are completely indepen-
dent of tubular damage, and of mechanisms derived from
tubular damage that alter glomerular and vascular function.
Finally, it should be stressed that known and new nephro-
protective strategies should also be tested for their potential
effects on the bactericidal effect of aminoglycosides. This issue
has not been addressed in renal studies. For example, oxidative
stress has been proposed to contribute to aminoglycoside
bactericidal effect.167 Then, treatment with antioxidants with
the objective of reducing their nephrotoxicity may also impair
their antibiotic activity. Thus, combined models of nephrotoxi-
city/nephroprotection and sepsis should be developed.
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